Next, we assessed that the diversity of TCR repertoires of tumor-specific CD4+Teffs and Tregs in pLN, dLN, and tumor in treated and untreated mice was assessed by counting numbers of tumor-reactive CD4+Teffs and Tregs clones. The gene discussed is CD4; the disease is neoplasm.